The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.